DE60028970D1 - An her2 bindende peptidverbindungen - Google Patents

An her2 bindende peptidverbindungen

Info

Publication number
DE60028970D1
DE60028970D1 DE60028970T DE60028970T DE60028970D1 DE 60028970 D1 DE60028970 D1 DE 60028970D1 DE 60028970 T DE60028970 T DE 60028970T DE 60028970 T DE60028970 T DE 60028970T DE 60028970 D1 DE60028970 D1 DE 60028970D1
Authority
DE
Germany
Prior art keywords
binding peptide
peptide compounds
novel compounds
her2 binding
erbb2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60028970T
Other languages
English (en)
Other versions
DE60028970T2 (de
Inventor
S Dennis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60028970D1 publication Critical patent/DE60028970D1/de
Publication of DE60028970T2 publication Critical patent/DE60028970T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
DE60028970T 1999-07-02 2000-06-30 An her2 bindende peptidverbindungen Expired - Lifetime DE60028970T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14223299P 1999-07-02 1999-07-02
US142232P 1999-07-02
PCT/US2000/018283 WO2001001748A2 (en) 1999-07-02 2000-06-30 Peptide compounds that bind her2

Publications (2)

Publication Number Publication Date
DE60028970D1 true DE60028970D1 (de) 2006-08-03
DE60028970T2 DE60028970T2 (de) 2007-02-15

Family

ID=22499090

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60028970T Expired - Lifetime DE60028970T2 (de) 1999-07-02 2000-06-30 An her2 bindende peptidverbindungen

Country Status (9)

Country Link
US (1) US6987088B2 (de)
EP (1) EP1189931B1 (de)
JP (2) JP4387625B2 (de)
AT (1) ATE330967T1 (de)
AU (1) AU779612C (de)
CA (1) CA2373721C (de)
DE (1) DE60028970T2 (de)
IL (2) IL147271A0 (de)
WO (1) WO2001001748A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) † 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
AU2002365258A1 (en) * 2001-10-12 2003-09-02 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of erbb2 and uses therefor
KR101166214B1 (ko) 2002-01-17 2012-07-16 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법
DE50307984D1 (de) * 2002-03-01 2007-09-27 Volker A Erdmann Streptavidin-Bindungspeptid
DE10208877B4 (de) * 2002-03-01 2009-04-09 Erdmann, Volker A., Prof.Dr. Verwendung eines Streptavidin- Bindungspeptides
US7785829B2 (en) * 2003-03-19 2010-08-31 Biogen Idec Ma, Inc. Nogo receptor binding protein
CA2531238C (en) * 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
CA2560759A1 (en) * 2004-03-03 2005-12-22 Iq Corporation Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
US20050265966A1 (en) * 2004-05-20 2005-12-01 Kindsvogel Wayne R Methods of treating cancer using IL-21 and monoclonal antibody therapy
BRPI0512500A (pt) 2004-06-24 2008-03-11 Biogen Idec Inc tratamento ou condições envolvendo desmielinação
ES2521140T3 (es) * 2004-07-22 2014-11-12 Genentech, Inc. Composición de anticuerpos de HER2
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
JP4937138B2 (ja) 2005-01-05 2012-05-23 エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 相補性決定領域とは異なる分子の領域に設計された結合性を持つ合成免疫グロブリンドメイン
BRPI0613387A2 (pt) 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
EP1951277A2 (de) * 2005-10-14 2008-08-06 Biorexis Pharmaceutical Corporation Mit natriuretischem peptid modifizierte transferrin-fusionsproteine
EP1965827B1 (de) 2005-12-02 2015-02-25 Biogen Idec MA Inc. Behandlung von entmyelinisierenden erkrankungen
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
LT2511301T (lt) * 2006-08-04 2018-04-10 Medimmune Limited Žmogaus antikūnas prieš erbb2
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
WO2009000006A1 (en) 2007-06-26 2008-12-31 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Display of binding agents
AU2008311251B9 (en) * 2007-10-11 2014-04-17 Biogen Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and TrkB agonists
CA2702630C (en) * 2007-11-08 2017-11-21 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
NZ590605A (en) * 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
EP2145901B1 (de) 2008-07-18 2012-11-14 Technische Universität Braunschweig Rekombinante anti-MUC1-Antikörper
US9586996B2 (en) * 2010-04-30 2017-03-07 Esperance Pharmaceuticals, Inc. Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
KR101782671B1 (ko) * 2011-03-28 2017-09-27 에스.아이.에스. 슐로브 이노베이티브 사이언스 리미티드 피부 질환을 치료하는 방법
KR102231139B1 (ko) 2011-06-28 2021-03-24 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
WO2015138452A1 (en) 2014-03-11 2015-09-17 Molecular Templates, Inc. Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
CN114656573A (zh) 2015-05-30 2022-06-24 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
EP3325510A2 (de) 2015-07-26 2018-05-30 Molecular Templates, Inc. Gegen zellen gerichtete moleküle mit effektoren der shigatoxin-a-untereinheit und cd8+-t-zellepitopen
WO2017200787A1 (en) 2016-05-18 2017-11-23 Arizona Board Of Regents On Behalf Of Arizona State University Peptide-dna chimeras for treatment of her overexpressing cancers
CN109642233A (zh) * 2016-09-06 2019-04-16 中央研究院 ErbB2调控自噬潮以调节阿尔兹海默症的APP-CTF的蛋白质内稳态
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US5279966A (en) * 1992-04-02 1994-01-18 The Trustees Of Columbia University In The City Of New York Cloning, expression and uses of a novel secreted protein, F-spondin
US5871969A (en) * 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
KR20060079258A (ko) * 1996-10-18 2006-07-05 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
CA2295317A1 (en) * 1997-06-17 1998-12-23 Human Genome Sciences, Inc. Heregulin-like factor
WO1999014323A1 (en) * 1997-09-17 1999-03-25 Urs Eppenberger Heregulin-gamma
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1053009B1 (de) * 1998-02-04 2004-09-22 Genentech, Inc. Verwendung des heregulins als epithelzellenwachstumsfaktor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists

Also Published As

Publication number Publication date
AU6066900A (en) 2001-01-22
WO2001001748A2 (en) 2001-01-11
IL147271A (en) 2014-07-31
AU779612B2 (en) 2005-02-03
JP2003503075A (ja) 2003-01-28
WO2001001748A3 (en) 2001-07-26
JP2010004885A (ja) 2010-01-14
US6987088B2 (en) 2006-01-17
CA2373721C (en) 2013-10-15
EP1189931A2 (de) 2002-03-27
CA2373721A1 (en) 2001-01-11
AU779612C (en) 2005-12-15
EP1189931B1 (de) 2006-06-21
DE60028970T2 (de) 2007-02-15
ATE330967T1 (de) 2006-07-15
US20030171278A1 (en) 2003-09-11
IL147271A0 (en) 2002-08-14
JP4387625B2 (ja) 2009-12-16

Similar Documents

Publication Publication Date Title
DE60028970D1 (de) An her2 bindende peptidverbindungen
EP1408986A4 (de) Proteomimetische verbindungen und verfahren
GB0222495D0 (en) Compounds
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
AU3368497A (en) Human dnase i hyperactive variants
NO20055209D0 (no) Peptabody for cancerbehandling
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
AU2003260436A1 (en) Pyrimidine compounds
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2003102185A3 (en) Methods and compositions for treating neoplasia relating to hnrnp a1 and a2 nucleic acid molecules
IL154522A0 (en) IgE RECEPTOR ANTAGONISTS
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
IL207012A (en) 28sgp medicinal product and 28sgp accent cancer treatment vaccine
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004031354A3 (en) Human sarcoma-associated antigens
SG148195A1 (en) Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
WO2004004649A3 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition